Krystal Biotech (KRYS) FCF Margin (2023 - 2026)

Krystal Biotech has disclosed FCF Margin across 4 years of filings, most recently posting 62.94% for Q1 2026.

• FCF Margin for Q1 2026 came in at 62.94%, up 2940.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 57.87% (up 1549.0% YoY), and the FY2025 annual result was 50.83%, up 981.0% from the prior year.
• FCF Margin came in at 62.94% for Q1 2026 at Krystal Biotech, down from 70.09% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 70.09% in Q4 2025 to a low of 249.31% in Q3 2023.
• The 4-year median for FCF Margin is 47.94% (2025), against an average of 13.39%.
• Across the five-year window, FCF Margin jumped 31826 bps in 2024 and tumbled 2075 bps in 2025, its largest moves.
• Krystal Biotech's FCF Margin stood at 11.23% in 2023, then jumped by 609 bps to 57.12% in 2024, then gained by 23 bps to 70.09% in 2025, then fell by 10 bps to 62.94% in 2026.
• The last three FCF Margin figures came in at 62.94% (Q1 2026), 70.09% (Q4 2025), and 48.2% (Q3 2025), per Business Quant data.